

MS Rec'd PCT 10 03 MAR 2006

Docket No.: 0933-0241PUS1
(PATENT)

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jukka T. SALONEN et al.

Application No.: 10/530,347

Confirmation No.: 7762

Filed: April 6, 2005

Art Unit: N/A

For: DETECTING THE RISK OF
CARDIOVASCULAR DISEASE BY
DETECTING MUTATIONS IN GENES,
INCLUDING GENES ENCODING A2B
ADRENOCEPTOR AND APOLIPOPROTEIN
B

Examiner: Not Yet Assigned

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notification of Missing Requirements dated January 5, 2006, Applicant respectfully submits:

- Attached is a copy of the Notification of Missing Requirements (371 Formalities Letter).
- Attached is the Executed Declaration and Power of Attorney Original Photocopy.
- The specification attached to the executed Declaration and Power of Attorney is a true copy of the specification that was filed in the U.S. Patent and Trademark Office on April 6, 2005, including any amendments thereto (if applicable) filed on even date therewith.

The undersigned hereby declares that "Attorney Docket No. 0933-0241PUS1" on page 1 of the attached Inventors' Declaration corresponds to Appl. No. 10/530,347 filed April 6, 2005 entitled "DETECTING THE RISK OF CARDIOVASCULAR DISEASE BY DETECTING MUTATIONS IN GENES, INCLUDING GENES ENCODING A2B ADRENOCEPTOR AND APOLIPOPROTEIN B."

Attached is an English language translation of the above-identified application that was filed in a foreign language, which should be used as the copy for examination purposes.

See the attached Translator's Verification; or

The undersigned states that the English translation attached hereto is a true and correct translation of the application as originally filed in a foreign language.

Attached are @@@ sheet(s) of drawings. Please substitute these replacement drawings for the corresponding @@@ sheet(s) of drawings on file in the above-identified application.

Attached are substitute claims commencing on a separate sheet in accordance with 37 C.F.R. § 1.75(h).

Attached is a substitute abstract commencing on a separate sheet in accordance with 37 C.F.R. § 1.72(b).

Attached is a substitute specification that complies with 37 C.F.R. § 1.52. The substitute specification does not contain new matter.

Attached is an amendment, Sequence Listing and disc.

Applicant claims small entity status under 37 C.F.R. § 1.27.


Attached is a Supplemental Application Data Sheet (ADS).

- Submitted concurrently herewith under separate cover for recording is an Assignment.
- Attached is a Petition for Extension of Time.
- The Government Filing Surcharge for late filing of oath and/or declaration in the amount of \$130.00 in accordance with 37 C.F.R. §§ 1.494 and 1.492 was previously paid for concurrently with the filing of the application on April 6, 2005.
- Attached hereto is the fee transmittal listing the required fees.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: March 6, 2006

Respectfully submitted,

By 
Gerald M. Murphy, Jr.
Registration No. 28,977
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

Attachment(s)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/530,347	Jukka T Salonen	0933-0241PUS1
		INTERNATIONAL APPLICATION NO.
		PCT/FI03/00740
I.A. FILING DATE		PRIORITY DATE
10/07/2003		10/07/2002
KEN O' M DOCKETED <i>Perfect Sequence listing 3-5-06</i>		
CONFIRMATION NO. 7762 371 FORMALITIES LETTER  *OC000000017790070*		

Date Mailed: 01/05/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 04/06/2005
- Copy of the International Search Report filed on 04/06/2005
- Preliminary Amendments filed on 04/06/2005
- Information Disclosure Statements filed on 04/06/2005
- U.S. Basic National Fees filed on 04/06/2005
- Specification filed on 04/06/2005
- Claims filed on 04/06/2005
- Abstracts filed on 04/06/2005
- Paper nucleotide sequence listings filed on 04/06/2005

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in

computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

TAMALA D HOLLAND

Telephone: (703) 308-9140 EXT 209

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/530,347	PCT/FI03/00740	0933-0241PUS1

AMENDMENT TRANSMITTAL LETTERDocket No.
0933-0241PUS1

Application No. 10/530,347-Conf. #7762	Filing Date April 6, 2005	Examiner Not Yet Assigned	Art Unit N/A
---	------------------------------	------------------------------	-----------------

Applicant(s): Jukka T. SALONEN et al.

DETECTING THE RISK OF CARDIOVASCULAR DISEASE BY DETECTING MUTATIONS
Invention: IN GENES, INCLUDING GENES ENCODING A2B ADRENOCEPTOR AND
APOLIPOPROTEIN B

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	23	- 23 =		X	
Independent Claims	2	- 3 =		X	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00

 Large Entity Small Entity No additional fee is required for this amendment. Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed. A check in the amount of \$ _____ is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge and credit Deposit Account No. 02-2448
as described below. A duplicate copy of this sheet is enclosed. Credit any overpayment. Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.
Gerald M. Murphy, Jr.
Attorney Reg. No.: 28,977

Dated: March 6, 2006

BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000